Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC)
Publication
, Conference
Vlahovic, G; Foster, TL; Andrews, CH; Herndon, JE; Sporn, T; Kelley, MJ; Dewhirst, MW; Vujaskovic, Z
Published in: JOURNAL OF CLINICAL ONCOLOGY
June 20, 2007
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 20, 2007
Volume
25
Issue
18
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Vlahovic, G., Foster, T. L., Andrews, C. H., Herndon, J. E., Sporn, T., Kelley, M. J., … Vujaskovic, Z. (2007). Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 25). AMER SOC CLINICAL ONCOLOGY.
Vlahovic, G., T. L. Foster, C. H. Andrews, J. E. Herndon, T. Sporn, M. J. Kelley, M. W. Dewhirst, and Z. Vujaskovic. “Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
Vlahovic G, Foster TL, Andrews CH, Herndon JE, Sporn T, Kelley MJ, et al. Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.
Vlahovic, G., et al. “Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18, AMER SOC CLINICAL ONCOLOGY, 2007.
Vlahovic G, Foster TL, Andrews CH, Herndon JE, Sporn T, Kelley MJ, Dewhirst MW, Vujaskovic Z. Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
June 20, 2007
Volume
25
Issue
18
Publisher
AMER SOC CLINICAL ONCOLOGY
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences